Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anileridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 0.69 |
| ▸ | OPRK1 known ✓ | P41145 | 6/20 | 0.69 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.72 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.69 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.63 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anileridine SCHEMBL7119028 | 1.00 | KCNA3 (0.72) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL27722317 | 0.99 | KCNA3 (0.74) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL26333 | 0.99 | KCNA3 (0.74) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL1237724 | 0.95 | KCNA3 (0.69) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Pheneridine SCHEMBL1922392 | 0.91 | KCNA3 (0.86) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Anileridine SCHEMBL8741179 | 0.90 | KCNA3 (0.66) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Phenoperidine SCHEMBL28832646 | 0.90 | KCNA3 (0.67) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL7313939 | 0.84 | KCNA3 (1.00) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| SCHEMBL11712840 | 0.82 | OPRM1 (0.82) | KCNA3OPRM1OPRD1OPRK1SLC22A1 | |
| Hydrochloric Acid SCHEMBL11603600 | 0.82 | OPRM1 (0.79) | KCNA3OPRM1OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170112829-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-04-27 | — | — | US | claimed |
| US-20110052723-A1 | USE OF COMPOUNDS BINDING TO THE SIGMA RECEPTOR LIGANDS FOR THE TREATMENT OF NEUROPATHIC PAIN DEVELOPING AS A CONSEQUENCE OF CHEMOTHERAPY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-03-03 | — | — | US | claimed |
| WO-2010101649-A2 | SIGMA 1 RECEPTOR INHIBITION AS A NOVEL THERAPEUTICAL APPROACH AGAINST HEPATITIS C VIRUS INFECTION | GASTAMINZA PABLO (US) | 2010-09-10 | — | — | WO | claimed |
| EP-2090311-A1 | Use of compounds binding to the sigma receptor ligands for the treatment of neuropathic pain developing as a consequence of chemotherapy | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-08-19 | — | — | EP | claimed |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-07-16 | — | — | US | claimed |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2009-02-12 | — | — | US | claimed |
| EP-1829534-A1 | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | claimed |
| CN-1988896-A | Use of compounds active on the sigma receptor for the treatment of mechanical allodynia | ESTEVE LABOR DR (ES) | 2007-06-27 | — | — | CN | claimed |
| EP-1787679-A1 | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | WATSON JOHN W (US) | 2003-09-18 | — | — | US | claimed |
| EP-4719353-A1 | REVERSIBLE SURFACTANT AND MULTIFUNCTIONAL DRUG DELIVERY SYSTEMS BASED THEREON | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-04-08 | — | — | EP | disclosed |
| US-12590054-B2 | Use of D9-methadone for postoperative pain relief | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-31 | — | — | US | disclosed |
| WO-2025109604-A1 | DOLASTATIN 10 ANALOGS | Ariel Scientific Innovations Ltd. (IL) | 2025-05-30 | — | — | WO | disclosed |
| US-20250152319-A1 | ORAL APPLIANCE FOR DELIVERY OF MEDICAMENTS AND/OR OTHER SUBSTANCES | Emanate Biomedical, Inc. (US) | 2025-05-15 | — | — | US | disclosed |
| US-12296085-B2 | Method for extracorporeal treatment of preeclampsia and related disorders | ImMutriX Therapeutics, Inc. (US) | 2025-05-13 | — | — | US | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| US-5578645-A | Methods and compositions for treating acute or chronic pain and drug addiction | AMINOTEK SCIENCES, INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5256669-A | Methods and compositions for treating acute or chronic pain and drug addiction | AMINOTEK SCIENCES, INC. (US) | 1993-10-26 | — | — | US | disclosed |
| EP-0212875-A2 | Medicinal composition and method of making same | Tucker, William Gough (US) | 1987-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590054-B2 | Use of D9-methadone for postoperative pain relief | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885OPRK1 3/4885KCNA3 899/4885 |
| US-20090042898-A1 | USE OF COMPOUNDS ACTIVE ON THE SIGMA RECEPTOR FOR THE TREATMENT OF MECANICAL ALLODYNIA | OPRM1, OPRL1, OPRK1 | OPRM1 1/4885OPRK1 3/4885KCNA3 591/4885 |
| US-20090181976-A1 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome | SIGMAR1, GPR119, TMEM97 | OPRM1 11/4885OPRK1 6/4885KCNA3 1912/4885 |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRK1 2/4885KCNA3 2089/4885 |
| US-12296085-B2 | Method for extracorporeal treatment of preeclampsia and related disorders | TEK, FLT4, PGF | OPRM1 4455/4885OPRK1 4012/4885KCNA3 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.